Definium Therapeutics, Inc.
DFTX
$42.63
-$1.27-2.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 72.90M | 57.58M | 48.64M | 45.29M | 38.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 227.54M | 193.37M | 166.31M | 151.19M | 130.32M |
| Operating Income | -227.54M | -193.37M | -166.31M | -151.19M | -130.32M |
| Income Before Tax | -353.79M | -237.54M | -183.79M | -168.10M | -114.52M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -353.79 | -237.54 | -183.79 | -168.10 | -114.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -353.79M | -237.54M | -183.79M | -168.10M | -114.52M |
| EBIT | -227.54M | -193.37M | -166.31M | -151.19M | -130.32M |
| EBITDA | -93.23M | -134.13M | -166.28M | -151.17M | -130.30M |
| EPS Basic | -3.43 | -2.49 | -2.06 | -1.97 | -1.36 |
| Normalized Basic EPS | -2.14 | -1.56 | -1.29 | -1.23 | -0.85 |
| EPS Diluted | -3.43 | -2.49 | -2.13 | -2.05 | -1.54 |
| Normalized Diluted EPS | -2.14 | -1.56 | -1.28 | -1.23 | -0.85 |
| Average Basic Shares Outstanding | 406.36M | 381.02M | 357.30M | 340.23M | 332.26M |
| Average Diluted Shares Outstanding | 406.36M | 381.02M | 359.33M | 342.26M | 336.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |